Boston Scientific Corporation announced a series of leadership changes in a Form 8-K filed on October 1, 2026, with the effective dates for the new roles set for January 1, 2027. The company promoted Joseph M. Fitzgerald to Executive Vice President and Chief Operating Officer (COO). Mr. Fitzgerald, age 63, is currently the Executive Vice President and Group President of the Cardiovascular business and will assume the COO role on January 1, 2027.
In his new position, Mr. Fitzgerald will oversee the company’s global operations, business units, and regions. The company also revealed a new operating structure that will establish three reportable segments effective January 1: Interventional Therapies, Rhythm Solutions, and MedSurg. Mr. Fitzgerald will report to Mike Mahoney, the Chairman and Chief Executive Officer.
The new segment leadership includes Lance Bates as Executive Vice President and President of Interventional Therapies, Nick Spadea-Anello as Executive Vice President and President of Rhythm Solutions, and Stephen Morse as Executive Vice President and President of MedSurg and Asia Pacific. The Interventional Therapies segment will include Interventional Cardiology, Vascular Therapies, and Interventional Oncology & Embolization businesses, while Rhythm Solutions will include Electrophysiology, WATCHMAN, and Cardiac Rhythm Management & Diagnostics. The MedSurg segment will encompass Endoscopy, Urology, and Neuromodulation.
The filing details the compensation package for Mr. Fitzgerald, effective January 1, 2027. His annual base salary is set at $1,050,000. He is eligible for an annual bonus with a target percentage of 110% of his base salary and can defer up to 75% of his annual bonus. Additionally, he will receive an annual equity award for 2027 with a total grant date fair value of $7,000,000, consisting of non-qualified stock options and restricted stock units, including performance-based RSUs, vesting 25% per year.
Separately, the company announced the appointment of Mark Bickel, age 49, as Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027. Mr. Bickel is currently the Senior Vice President of Finance and Global Controller of the Cardiovascular business. He replaces Emily Woodworth (Collins), who will transition to Senior Vice President, Global Finance Controller and Finance Transformation on March 1, 2027, ending her tenure as Chief Accounting Officer. The filing notes that Ms. Woodworth’s transition is not due to any disagreements with the company regarding financial statements or operations.
